THE IMPACT OF 12-MONTH GROWTH HORMONE REPLACEMENT THERAPY ON LIPID METABOLISM AND ADIPOSE TISSUE DISTRIBUTION IN GEORGIAN PATIENTS WITH ADULT GROWTH HORMONE DEFICIENCY.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The aim of their study was to evaluate the impact of growth hormone (GH) replacement therapy on lipid profile and adipose tissue distribution in adults with GHD.

Why It Was Studied

The patients were selected from the basis of National Institute of Endocrinology.

Who Took Part

According to the abstract, 10 patients were involved.

PubMed tags the participants as both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

Neither the patients nor the staff measuring them knew who was on Exogenous HGH, sermorelin & older GHRPs (why they're passed over), so expectations could not easily colour the readings.

Some patients received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.

What Was Measured

Topics PubMed links to this paper include Adipose Tissue, Case-Control Studies, Growth Hormone, Hormone Replacement Therapy, Human Growth Hormone, Hypopituitarism and Lipid Metabolism.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 10 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2017 (Georgian medical news), a journal based in Georgia (Republic).

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.